真实世界ARCA注册研究:RA合并既往癌症患者使用bDMARDs与tsDMARDs后新发原发癌、局部进展或转移风险
ARCA注册研究为全国性回顾性研究,纳入728例类风湿关节炎合并既往癌症患者,比较不同DMARDs策略下新发原发癌、局部进展或转移风险。以csDMARDs为参照,各bDMARDs及tsDMARDs调整后HR均无显著差异,未发现不同DMARDs策略间癌症风险存在差异。
要点
- 总体癌症发生率7.3/1000人年(95%CI 5.8-9.0)。
- 与csDMARDs相比,TNF抑制剂、IL6抑制剂、CD20抑制剂、tsDMARDs及CTLA4类似物调整后HR均无显著差异。
核心结论
- 真实世界数据未发现RA合并既往癌症患者在不同DMARDs策略间新发原发癌、局部进展或转移风险存在差异。
研究设计与样本
- ARthritis and CAncer注册研究为全国性回顾性研究,纳入728例RA合并既往癌症患者,收集RA特征、DMARDs使用、癌症类型及人口学资料,采用调整Cox回归模型估计HR,以csDMARDs为参照。
主要发现
- 与csDMARDs相比,所有癌症调整后HR(95%CI)为:TNF抑制剂0.94(0.73-1.21),IL6抑制剂1.03(0.61-1.74),CD20抑制剂0.81(0.46-1.42),tsDMARDs 0.6(0.26-1.4),CTLA4类似物0.74(0.41-1.34)。
- 调整暴露时间、高级治疗线数或既往癌症状态后,未观察到癌症风险差异。
关键数值与推荐
- 总体癌症发生率7.3/1000人年(95%CI 5.8-9.0)。
- TNF抑制剂 vs csDMARDs调整后HR 0.94(95%CI 0.73-1.21)。
- IL6抑制剂 vs csDMARDs调整后HR 1.03(95%CI 0.61-1.74)。
- CD20抑制剂 vs csDMARDs调整后HR 0.81(95%CI 0.46-1.42)。
- tsDMARDs vs csDMARDs调整后HR 0.6(95%CI 0.26-1.4);CTLA4类似物 vs csDMARDs调整后HR 0.74(95%CI 0.41-1.34)。
临床怎么用
- 对于RA合并既往癌症患者,选择bDMARDs或tsDMARDs时,现有真实世界数据未显示不同机制药物间癌症风险存在差异,可结合病情需要个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the risk of new primary cancer, locoregional progression or metastasis across different disease-modifying antirheumatic drugs (DMARDs) strategies in real-world patients with rheumatoid arthritis (RA) and prior cancer. METHODS: The ARthritis and CAncer registry is a nationwide retrospective study, including patients with RA and prior cancer. Collected variables included RA characteristics, DMARDs received, cancer type and demographics. The primary outcome was the occurrence of new primary cancer, locoregional progression or metastasis during follow-up. Adjusted Cox regression models were used to estimate HRs for cancer events. Treatment strategies involving conventional synthetic (cs)DMARDs served as the reference for comparison. RESULTS: Among 728 patients with RA, 80 cases of cancer were identified over a cumulative exposure period of 11 022 years, with an overall cancer incidence rate of 7.3 (95% CI 5.8 to 9.0) per 1000 person-years. Adjusted HRs for all cancers (95% CI) compared with csDMARDs were 0.94 (0.73 to 1.21) for tumour necrosis factor inhibitors, 1.03 (0.61 to 1.74) for IL6-inhibitors, 0.81 (0.46 to 1.42) for CD20 inhibitors, 0.6 (0.26 to 1.4) for targeted synthetic DMARDs and 0.74 (0.41 to 1.34) for cytotoxic T-lymphocyte-associated protein 4-analogue. No differences in cancer risk were observed after adjusting for duration of exposure, line of advanced therapy or prior cancer status. CONCLUSION: This real-world data did not identify differences in the risk of new primary cancer, locoregional progression or metastasis across different DMARDs strategies in patients with RA and prior cancer.
引用
- Molina-Collada J, Plasencia-Rodriguez C, García-García V, et al. Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry. RMD Open. 2026. PMID: 42791026. doi:10.1136/rmdopen-2026-007113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。